Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients

•cfDNA-NGS enabled rapid detection of tier 1 genomic variants in advanced NSCLC.•cfDNA-NGS increased the detection rate of tier 1 variants by 46% versus tissue alone.•The sensitivity of cfDNA-NGS relative to paired tissue tests was 75%.•Time from request to report was shorter for cfDNA-NGS versus standard tissue tests.•Time from sampling to treatment initiation was shorter for cfDNA-NGS versus tissue.